Chemomab reports FY2021 net loss of $12.5M; revises CM-101 clinical program to extend cash runway through end 2023

Chemomab Therapeutics Ltd.

Net loss $12.5M ($0.06 per share) in FY2021 vs $6.0M in FY2020; cash $61.2M at Dec 31, 2021.
Expanding Phase 2 PSC trial with dose-finding cohorts and open-label extension; interim analysis expected H2 2022.
Focusing SSc trial on earlier proof of concept; trial initiation anticipated H2 2022.
Winding down liver fibrosis subcutaneous formulation study; data readout targeted near end of 2022.
Cash runway extended ~6 months to end of 2023; company expects 3-4 data readouts over next 24 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.